Physician profile
Emily R Downs
NPI 1598320087
$4,957.24
in general payments reported to CMS, 2019-2025
33 companies · $1,165 in 2025
The $1,165 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $529 · 2022: $932 · 2023: $1,188 · 2024: $1,143 · 2025: $1,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,207 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,207.11 |
| Education | $288.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $800.85 | 2021-2025 | |
| Astellas Pharma US INC | $742.36 | 2021-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $455.91 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $435.80 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $369.57 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $308.67 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $212.19 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $146.85 | 2023-2025 | Krystexxa, Evenity, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $146.24 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $139.39 | 2021-2025 | Spravato |
| Exact Sciences Corporation | $132.90 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Medtronic, INC. | $114.19 | 2024-2025 | Interstim, Intellis Adaptivestim |
| Teleflex LLC | $106.57 | 2024 | Urolift |
| Abbott Laboratories | $103.15 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.01 | 2021-2024 | Ofev |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $82.07 | 2021-2025 | Wellbutrin, Aplenzin |
| Inspire Medical Systems, INC. | $76.90 | 2025 | Inspire |
| Dexcom, INC. | $67.81 | 2025 | Dexcom G6 Transmitter |
| Tris Pharma INC | $48.61 | 2023 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.88 | 2025 | Caplyta |
| Boston Scientific Corporation | $38.07 | 2025 | General - Pain Management, Varithena Administration Pack |
| Esperion Therapeutics, INC. | $37.56 | 2021 | |
| Linus Health, INC. | $35.80 | 2022 | |
| Novartis Pharmaceuticals Corporation | $34.14 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.22 | 2022-2025 | |
| Shield Therapeutics INC | $22.71 | 2022 | |
| Genentech USA, INC. | $22.04 | 2021 | |
| Merck Sharp & Dohme LLC | $21.58 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.50 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $20.80 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.98 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.80 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Downs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.